FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

The Lancet Gastroenterology & Hepatology - Tập 5 - Trang 362-373 - 2020
Philip N Newsome1,2,3, Magali Sasso4, Jonathan J Deeks1,5, Angelo Paredes6,7, Jérôme Boursier8,9, Wah-Kheong Chan10, Yusuf Yilmaz11,12, Sébastien Czernichow13, Ming-Hua Zheng14,15, Vincent Wai-Sun Wong16, Michael Allison17, Emmanuel Tsochatzis18, Quentin M Anstee19,20, David A Sheridan21, Peter J Eddowes22, Indra N Guha22, Jeremy F Cobbold23, Valérie Paradis24, Pierre Bedossa20,25, Véronique Miette4
1National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK
2Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
3Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
4R&D Department, Echosens, Paris, France
5Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
6Brooke Army Medical Center, Fort Sam, Houston, TX. USA
7Uniformed Services University of the Health Sciences, Bethesda, MD USA
8Department of Hepato-Gastroenterology, Angers University Hospital, Angers, France
9HIFIH Laboratory UPRES EA3859, SFR4208, Angers University, Angers, France
10Gastroenterology and Hepatology Unit, Gastrointestinal Endoscopy Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
11Liver Research Unit, Institute of Gastroenterology, Marmara University, Istanbul, Turkey
12Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey
13Department of Nutrition, Hôpital Européen Georges-Pompidou (APHP), University of Paris, Paris, France
14NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
15Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
16Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
17Department of Medicine, Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
18UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK
19Institute of Cellular Medicine–Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
20Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
21Institute of Translational and Stratified Medicine, University of Plymouth, Plymouth, UK
22NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
23NIHR Oxford Biomedical Research Centre and Oxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
24Pathology Department, Hôpital Beaujon, APHP, Clichy, France
25Liverpat, Paris, France

Tài liệu tham khảo

Younossi, 2017, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Haldar, 2019, Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study, J Hepatol, 71, 313, 10.1016/j.jhep.2019.04.011 Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061 Tsochatzis, 2018, Non-alcoholic fatty liver disease and the interface between primary and secondary care, Lancet Gastroenterol Hepatol, 3, 509, 10.1016/S2468-1253(18)30077-3 Sanyal, 2019, Past, present and future perspectives in nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 16, 377, 10.1038/s41575-019-0144-8 Srivastava, 2019, Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease, J Hepatol, 71, 371, 10.1016/j.jhep.2019.03.033 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers, Hepatology, 47, 455, 10.1002/hep.21984 Sanyal, 2015, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases—US Food and Drug Administration Joint Workshop, Hepatology, 61, 1392, 10.1002/hep.27678 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038 Moons, 2015, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration, Ann Intern Med, 162, W1, 10.7326/M14-0698 Collins, 2015, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement, BMJ, 350, 10.1136/bmj.g7594 Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173 Sandrin, 2003, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001 Sasso, 2010, Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 Harrell, 2006 Steyerberg, 2008 Steyerberg, 2014, Risk prediction with machine learning and regression methods, Biom J, 56, 601, 10.1002/bimj.201300297 2018 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Friedman, 2018, A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis, Hepatology, 67, 1754, 10.1002/hep.29477 Poynard, 2008, Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update, Gastroenterol Clin Biol, 32, 8, 10.1016/S0399-8320(08)73990-3 Vuppalanchi, 2018, Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease, Hepatology, 67, 134, 10.1002/hep.29489
Thông tin
Thông tin xuất bản

The Lancet Gastroenterology & Hepatology

Tập 5

362-373

Thông tin tác giả